STOCK TITAN
  1. Home
  2. Sec-filings
  3. RCUS
  4. [Form 4] Arcus Biosciences, Inc. Insider Trading Activity

Director David L. Lacey receives RCUS stock awards at Arcus Biosciences (RCUS)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Arcus Biosciences director David L. Lacey received new equity awards on common stock. He was granted 5,700 restricted stock units, increasing his direct common stock holdings to 76,652 shares after the award.

He also received a stock option for 16,900 shares with an exercise price of $23.30 per share, expiring on June 10, 2036. Both the RSUs and the option vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, and each will become fully vested if the company is subject to a change in control.

Positive

  • None.

Negative

  • None.
Insider Lacey David L.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 16,900 $0.00 --
Grant/Award Common Stock 5,700 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 16,900 shares (Direct, null); Common Stock — 76,652 shares (Direct, null)
Footnotes (1)
  1. Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
RSUs granted 5,700 units Restricted stock units granted to director on June 11, 2026
Options granted 16,900 shares Stock option award to buy common stock
Option exercise price $23.30 per share Strike price for 16,900-share option grant
Option expiration June 10, 2036 Expiration date of stock option grant
Shares held after grant 76,652 shares Director’s direct common stock holdings following RSU grant
restricted stock units financial
"Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
change in control financial
"The RSUs will become fully vested in the event the Company is subject to a change in control."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
stock option financial
"The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
annual meeting of stockholders financial
"vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lacey David L.
(Last)(First)(Middle)
C/O ARCUS BIOSCIENCES, INC.
3928 POINT EDEN WAY
(Street)
HAYWARD CALIFORNIA 94545
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/11/2026A5,700(1)A$076,652D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$23.306/11/2026A16,900 (2)06/10/2036Stock Option (Rights to Buy)16,900$016,900D
Explanation of Responses:
1. Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
2. The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Remarks:
/s/ Carolyn Tang, Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Arcus Biosciences (RCUS) grant to David L. Lacey?

Arcus Biosciences granted David L. Lacey 5,700 restricted stock units and a stock option for 16,900 shares of common stock. These awards are compensation-related grants, not open-market purchases, and were reported as acquisitions on a Form 4 filing.

What is the vesting schedule for David L. Lacey’s new RCUS RSUs and options?

Both the 5,700 RSUs and the 16,900-share stock option vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders. This means vesting timing depends on when the company next holds its annual shareholder meeting.

At what price can David L. Lacey exercise his new Arcus Biosciences stock options?

The new stock option granted to David L. Lacey has an exercise price of $23.30 per share for 16,900 shares of common stock. The option expires on June 10, 2036, giving a long window to exercise after vesting conditions are met.

How many Arcus Biosciences shares does David L. Lacey hold after this Form 4?

Following the grant of 5,700 restricted stock units, David L. Lacey directly owns 76,652 shares of common stock. This figure reflects his direct common stock holdings after the reported compensation-related acquisition on the Form 4.

What happens to David L. Lacey’s RCUS RSUs and options if there is a change in control?

If Arcus Biosciences is subject to a change in control, both the 5,700 RSUs and the 16,900-share stock option become fully vested. This accelerates vesting regardless of the original schedule tied to June 11, 2027 or the next annual meeting.

Are David L. Lacey’s recent RCUS transactions open-market buys or compensation grants?

The transactions are compensation grants, not open-market buys. The Form 4 lists them under code “A” as grant, award, or other acquisition, covering 5,700 restricted stock units and a 16,900-share stock option award.